表紙
市場調查報告書

兒童失神性癲癇(CAE)治療藥市場 - 市場規模,佔有率,預測,機會分析 2018年∼2026年

Childhood Absence Epilepsy Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

出版商 Coherent Market Insights 商品編碼 754985
出版日期 內容資訊 英文 144 Pages
商品交期: 2-3個工作天內
價格
Back to Top
兒童失神性癲癇(CAE)治療藥市場 - 市場規模,佔有率,預測,機會分析 2018年∼2026年 Childhood Absence Epilepsy Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026
出版日期: 2018年12月04日內容資訊: 英文 144 Pages
簡介

兒童失神性癲癇,由腦波檢驗(EEG),視訊的遙測,MRI掃描,血液檢驗等診斷。構成癲癇的原因由MRI掃描確認,不過,為了確認癲癇的原因和疾病存在,有時也需要血液檢驗。

本報告提供全球兒童失神性癲癇(CAE)治療藥市場調查,市場概要,各治療藥、發作類型、地區的市場規模的變化與預測,市場趨勢,市場佔有率,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查目的與前提條件

  • 調查目的
  • 前提條件
  • 簡稱

第2章 市場概要

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
    • 市場片段:各治療藥物
    • 市場片段:各發作類型
    • 市場片段:各地區
  • 市場機會藍圖(COM)

第3章 市場動態,法規,趨勢分析

  • 關於兒童失神性癲癇(CAE)
  • 兒童失神性癲癇(CAE)的診斷
  • 治療方法
  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 法規方案
  • 開發平台分析

第4章 全球兒童失神性癲癇市場:各治療藥物

  • 簡介
  • Ethosuximide
  • Valproate
  • Lamotrigine
  • 第二階段實驗藥

第5章 全球兒童失神性癲癇市場:各發作類型

  • 簡介
  • 典型失神性發作
  • 非典型失神性發作

第6章 全球兒童失神性癲癇市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 非洲
  • 中東

第7章 競爭情形

  • 熱圖分析
  • 公司概要
    • Cavion, Inc.
    • Pfizer, Inc.
    • GlaxoSmithKline Plc
    • Insys Therapeutics, Inc.
    • AbbVie, Inc.
    • Teva Pharmaceutical Industries Ltd.

第8章 Section

  • 參考文獻
  • 調查方法
  • 關於Coherent Market Insights

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Childhood absence epilepsy diagnosis revolves around identifying symptoms and categorizing the epilepsy type based on those symptoms. Diagnostic methods and techniques for childhood absence epilepsy include electroencephalogram (EEG)/video telemetry, magnetic resonance imaging (MRI scans), and blood tests. In electroencephalogram (EEG)/video telemetry, electrical signals from brain are recorded in a computer by asking the patient to hyperventilate for 3 to 5 minutes, which triggers an absence seizure. The EEG then shows spikes and wave discharges at 3 Hz (cycles per second) that are generalized in nature (similar on both sides of the brain). Structural causes behind epilepsy can be understood with the help of MRI scans (as some patients suffering from epilepsy due to brain damage can be found by a MRI scan). Blood tests may be required to diagnose any medical conditions, which may be the reason behind epilepsy.

Market Dynamics

Key players in the market are focused on the development of new drugs for the treatment of childhood absence epilepsy. Factors such as increasing prevalence of the disease, increasing accessibility of medications, and presence of drugs in pipeline for childhood absence epilepsy treatment (Insys therapeutics and Cavion, Inc.) are expected to boost the global childhood absence epilepsy treatment market growth. Product launches by generic manufacturers in the U.S. as well as globally is expected to support growth of the market. For instance, Dr. Reddy's Laboratories launched generic lamotrigine orally disintegrating tablets in the U.S. in 2016. Moreover, a number of manufacturers such as Insys Therapeutics (Cannabidiol) and Cavion, Inc. (CX-8998) have drugs in phase II stage in clinical trials and these therapies are expected to be launched over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of childhood absence epilepsy treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2018-2026), considering 2016 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global childhood absence epilepsy treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
  • Key companies covered as a part of this study include Cavion, Inc., Pfizer, Inc., GlaxoSmithKline Plc, Insys Therapeutics, Inc., AbbVie, Inc., and Teva Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, by technology up-gradation, market expansion, and marketing tactics
  • The global childhood absence epilepsy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the childhood absence epilepsy treatment market

Detailed Segmentation:

  • Global Childhood Absence Epilepsy Treatment Market, By Drug:
    • Ethosuximide
    • Valproate
    • Lamotrigine
    • Phase 2 Drugs
      • Cannabidiol Oral Solution
      • CX-8998
  • Global Childhood Absence Epilepsy Treatment Market, By Disease Type:
    • Typical Absence Seizures
    • Atypical Absence Seizures
  • Global Childhood Absence Epilepsy Treatment Market, By Region:
    • North America
      • By Drug
      • Ethosuximide
      • Valproate
      • Lamotrigine
      • Phase 2 Drugs
      • Cannabidiol Oral Solution
      • CX-8998
      • By Disease Type:
      • Typical Absence Seizures
      • Atypical Absence Seizures
      • By Country:
      • U.S.
      • Canada
    • Europe
      • By Drug
      • Ethosuximide
      • Valproate
      • Lamotrigine
      • Phase 2 Drugs
      • Cannabidiol Oral Solution
      • CX-8998
      • By Disease Type:
      • Typical Absence Seizures
      • Atypical Absence Seizures
      • By Country:
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug
      • Ethosuximide
      • Valproate
      • Lamotrigine
      • Phase 2 Drugs
    • Cannabidiol Oral Solution
    • CX-8998
      • By Disease Type:
      • Typical Absence Seizures
      • Atypical Absence Seizures
      • By Country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
    • Latin America
      • By Drug
      • Ethosuximide
      • Valproate
      • Lamotrigine
      • Phase 2 Drugs
    • Cannabidiol Oral Solution
    • CX-8998
      • By Disease Type:
      • Typical Absence Seizures
      • Atypical Absence Seizures
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Middle East
      • By Drug
      • Ethosuximide
      • Valproate
      • Lamotrigine
      • Phase 2 Drugs
    • Cannabidiol Oral Solution
    • CX-8998
      • By Disease Type:
      • Typical Absence Seizures
      • Atypical Absence Seizures
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug
      • Ethosuximide
      • Valproate
      • Lamotrigine
      • Phase 2 Drugs
    • Cannabidiol Oral Solution
    • CX-8998
      • By Disease Type:
      • Typical Absence Seizures
      • Atypical Absence Seizures
      • By Country:
      • Central Africa
      • South Africa
      • North Africa
  • Company Profiles
    • Cavion, Inc. *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Pfizer, Inc.
    • GlaxoSmithKline Plc
    • Insys Therapeutics, Inc.
    • AbbVie, Inc.
    • Teva Pharmaceutical Industries Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug
    • Market Snippet, By Disease Type
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • About Childhood Absence Epilepsy
  • Diagnosis of Childhood Absence Epilepsy
  • Treatment Approaches
  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Regulatory Scenario
  • Pipeline Analysis

4. Global Childhood Absence Epilepsy Treatment Market, By Drug, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018-2026
    • Segment Trends
  • Ethosuximide
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Valproate
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Lamotrigine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Phase 2 Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
    • Cannabidiol Oral Solution
    • CX-8998

5. Global Childhood Absence Epilepsy Treatment Market, By Disease Type, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018-2026
    • Segment Trends
  • Typical Absence Seizures
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Atypical Absence Seizures
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)

6. Global Childhood Absence Epilepsy Treatment Market, By Region, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2026
  • North America
    • Market Size and Forecast, By Drug, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Market Size and Forecast, By Drug, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
  • Middle East
    • Market Size and Forecast, By Drug, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

7. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Cavion, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Insys Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AbbVie, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top